Ahn-Gook Pharmaceutical Co. Ltd Asset Resilience Ratio
Ahn-Gook Pharmaceutical Co. Ltd asset resilience ratio. Ahn-Gook Pharmaceutical Co. Ltd (001540) has an Asset Resilience Ratio of 3.23% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Ahn-Gook Pharmaceutical Co. Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ahn-Gook Pharmaceutical Co. Ltd (2011–2024)
Asset resilience ratio of Ahn-Gook Pharmaceutical Co. Ltd from 2011 to 2024. This chart shows how Ahn-Gook Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. Read 001540 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ahn-Gook Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ahn-Gook Pharmaceutical Co. Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩9.80 Billion | 3.23% |
| Total Liquid Assets | ₩9.80 Billion | 3.23% |
Asset Resilience Insights
- Limited Liquidity: Ahn-Gook Pharmaceutical Co. Ltd maintains only 3.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ahn-Gook Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Ahn-Gook Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Ahn-Gook Pharmaceutical Co. Ltd Asset Resilience Ratio by Year (2011–2024)
Ahn-Gook Pharmaceutical Co. Ltd asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Ahn-Gook Pharmaceutical Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.82% | ₩23.67 Billion ≈ $16.04 Million |
₩302.54 Billion ≈ $205.02 Million |
-2.13pp |
| 2023-12-31 | 9.96% | ₩23.75 Billion ≈ $16.10 Million |
₩238.60 Billion ≈ $161.69 Million |
-1.54pp |
| 2022-12-31 | 11.50% | ₩25.75 Billion ≈ $17.45 Million |
₩223.91 Billion ≈ $151.74 Million |
-8.96pp |
| 2021-12-31 | 20.46% | ₩43.33 Billion ≈ $29.37 Million |
₩211.80 Billion ≈ $143.53 Million |
-2.86pp |
| 2020-12-31 | 23.32% | ₩47.03 Billion ≈ $31.87 Million |
₩201.70 Billion ≈ $136.69 Million |
+3.30pp |
| 2019-12-31 | 20.02% | ₩43.64 Billion ≈ $29.58 Million |
₩217.96 Billion ≈ $147.71 Million |
+3.86pp |
| 2018-12-31 | 16.16% | ₩34.41 Billion ≈ $23.32 Million |
₩212.92 Billion ≈ $144.30 Million |
-1.08pp |
| 2017-12-31 | 17.24% | ₩35.87 Billion ≈ $24.31 Million |
₩208.07 Billion ≈ $141.00 Million |
+1.43pp |
| 2016-12-31 | 15.81% | ₩31.02 Billion ≈ $21.02 Million |
₩196.27 Billion ≈ $133.01 Million |
+5.41pp |
| 2015-12-31 | 10.40% | ₩20.57 Billion ≈ $13.94 Million |
₩197.85 Billion ≈ $134.08 Million |
-0.71pp |
| 2014-12-31 | 11.11% | ₩19.90 Billion ≈ $13.49 Million |
₩179.07 Billion ≈ $121.35 Million |
-5.27pp |
| 2013-12-31 | 16.38% | ₩26.74 Billion ≈ $18.12 Million |
₩163.24 Billion ≈ $110.63 Million |
-3.49pp |
| 2012-12-31 | 19.88% | ₩33.36 Billion ≈ $22.61 Million |
₩167.83 Billion ≈ $113.74 Million |
-2.10pp |
| 2011-12-31 | 21.98% | ₩36.01 Billion ≈ $24.40 Million |
₩163.85 Billion ≈ $111.04 Million |
-- |
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.